[Gan & Lee Pharmaceuticals: The first subject in the Phase I clinical trial of GLR2053 tablets has been administered] On November 9th, Gan & Lee Pharmaceuticals (603087.SH) announced that the Phase I clinical trial of GLR2053 tablets independently developed by the company in China has recently completed the administration of the first subject to the trial. GLR2053 tablets are an oral protein degradation targeted chimera (PROTAC) innovative drug independently developed by Ganli Pharmaceuticals and targeting signal transducer and activator of transcription 6 (STAT6). This clinical trial is planned to be used for the treatment of atopic dermatitis. As of the date of the announcement, no STAT6 PROTAC product has been approved for marketing globally. The company’s cumulative R&D investment is 71.6313 million yuan.